MD Anderson EGFR Classification Licensed By Bostongene And Tempus To Provide New Insight On Atypical Mutations In Lung Cancer
January 20, 2023
January 20, 2023
HOUSTON, Texas, Jan. 20 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Jan. 19, 2023:
* * *
Companies will provide classification information on EGFR mutations in non-small cell lung cancer that may guide clinical decision-making
* * *
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson EGFR Cl . . .
* * *
Companies will provide classification information on EGFR mutations in non-small cell lung cancer that may guide clinical decision-making
* * *
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson EGFR Cl . . .